Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 août 2018 14h00 HE | Source: Exonics Therapeutics

Exonics Announces Publication of Research Demonstrating Gene Repair Technology Restored Dystrophin Expression in Canine Model of Duchenne Muscular Dystrophy

Systemic delivery of SingleCut CRISPR gene editing components restored dystrophin expression to up to 92 percent of normal expression in heart muscle in canines First study of Exonics’ SingleCut...
30 janv. 2018 08h00 HE | Source: Exonics Therapeutics

Exonics Therapeutics Appoints Roger M. Perlmutter, M.D., Ph.D., to Board of Directors

CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne...
08 nov. 2017 07h30 HE | Source: Exonics Therapeutics

Exonics Therapeutics Raises $40 Million in Series A Financing

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne...
27 févr. 2017 07h30 HE | Source: Exonics Therapeutics

Exonics Therapeutics Launches with Funding from CureDuchenne Ventures to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy

BOSTON, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently correct a...